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Objective Mitochondrial disease is a disorder of energy
metabolism that affects 1 in 4300 adults in the UK. Pregnancy is
associated with physiological demands that have implications for
energy metabolism. We were interested to know how pregnancy
was affected in women with mitochondrial disease, particularly
those with the most common pathogenic mutation m.3243A>G.
Design Retrospective case-comparison study.
Population/Setting Sixty-seven women with genetically confirmed
mitochondrial disease from the UK Mitochondrial Diseases
Cohort and 69 unaffected women participated.
Methods Participants answered questionnaires regarding each of
their pregnancies. Patients were divided into two groups
according to genetic mutation, with those harbouring m.3243A>G
comprising a single group.
Main outcome measures Pregnancy-related complications, mode
of delivery, gestational age and birthweight of newborns.
Results Of 139 live births in the comparison group, 62 were in
the m.3243A>G group and 87 were in the ‘all other mutations’
group. Pregnancies of women with the m.3243A>G mutation had
significantly more gestational diabetes (odds ratio [OR] = 8.2,
95% CI 1.3–50.1), breathing difficulties (OR = 7.8, 95% CI 1.0–
59.1) and hypertension (OR = 8.2, 95% CI 3.1–21.5) than the
comparison group. Only half of the pregnancies in the
m.3243A>G group had normal vaginal delivery, with emergency
caesarean section accounting for 24.2% of deliveries. Babies were
born significantly earlier to mothers harbouring m.3243A>G with
53.3% of them preterm (<37 weeks). These babies were also more
likely to require resuscitation and admission.
Conclusion Women who carried the m.3243A>G mutation
appeared to be at higher risk of complications during pregnancies,
caesarean section and preterm delivery than the unaffected women
or those with other forms of mitochondrial disease.
Keywords Birthweight, breathing difficulties, gestation, gestational
diabetes, hypertension, m.3243A>G, mitochondria, mitochondrial
disease, MTTL1, pregnancy, pregnant women with mitochondrial
disease.
Tweetable abstract Pregnant women with mitochondrial disease –
m.3243A>G mutation – are at greatly increased risk of
complications and preterm delivery.
Please cite this paper as: Feeney CL, Lim AZ, Fagan E, Blain A, Bright A, Maddison J, Devine H, Stewart J, Taylor RW, Gorman GS, Turnbull DM, Nesbitt V,
McFarland R. A case-comparison study of pregnant women with mitochondrial disease – what to expect? BJOG 2019;126:1380–1389.
Introduction
Mitochondrial disease
Mitochondrial disease resulting from nuclear and mito-
chondrial DNA genetic mutations collectively affects 1 in
4300 adults in the UK.1,2 The most common pathogenic
point mutation of the mitochondrial genome is the
m.3243A>G in the MTTL1 gene, with a carrier rate of 1 in
400 individuals.3–5 This maternally inherited mutation is
implicated in several clinical syndromes such as
mitochondrial encephalopathy, lactic acidosis and stroke-
like episodes, maternally inherited deafness and diabetes,
and progressive external ophthalmoplegia.6,7 Affected
patients may also exhibit non-syndromic features such as
seizures, myopathy, ptosis, migraine, ataxia, gut dysmotility
or cognitive decline.7 Some case reports have highlighted
patients with mitochondrial disease who have suffered
obstetric complications or presented during pregnancy with
deterioration in their health.8,9 Carriers of m.3243A>G
seemed to have higher rates of obstetric complications than
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Maternal medicine
the general population.10 However, it remains unclear if
other pathogenic mutations are also associated with obstet-
ric complications.
Background
Mitochondrial disease typically affects organs with high
energy requirements such as the brain, skeletal muscle,
heart and liver.2 The normal physiological adaptations of
pregnancy are likely to have bio-energetic consequences
that increase the need for mitochondrial ATP production.
These additional demands on ATP supply during
pregnancy in the context of mitochondrial insufficiency
may be an important mechanism in maternal and fetal
complications.
Study objective
We hypothesised that mitochondrial dysfunction, with its
attendant decrease in ATP production, would predispose
women with mitochondrial diseases to high-risk pregnancy
and delivery, even before their disease became clinically
apparent. We attempted to identify these risks by inter-
viewing women who had been diagnosed with mitochon-
drial disease. In the UK, there has been no large-scale study
into the outcomes of pregnant women with mitochondrial
disease. Knowledge gained from this study may provide
insight into understanding the role of mitochondrial
genetic defects in adverse pregnancy outcomes.
Methods
Patient and comparison groups
Women aged >16 years with pathogenic genetic mutations
alongside compatible clinical and biochemical features were
recruited from the UK MRC Mitochondrial Disease Cohort
into the patient group. This group was further classified
into two genotypic subgroups; those with m.3243A>G
mutation and those with all other types of genetic muta-
tions causing mitochondrial disease. Genetic mutations
were analysed and confirmed by the NHS Highly Spe-
cialised Service for Rare Mitochondrial Disorders diagnostic
laboratory in Newcastle University, UK. In the comparison
group, we used unaffected family members of patients to
minimise socio-economic status and ethnicity as confound-
ing factors. An additional convenience sample of female
staff, regardless of roles, in three hospital wards in the
Royal Victoria Infirmary Newcastle were also recruited to
increase the size of the comparison group. Women in the
comparison group were matched to patients by their age in
the same year.
Main outcome measures
A patient focus group was consulted to design the ques-
tionnaire, together with input from the specialist
mitochondrial clinical team. Four main outcome measures
were selected for this study:
1 Fetal loss: miscarriage – spontaneous loss of pregnancy
before 24 weeks of gestation; stillbirth – baby delivered
with no signs of life at or after 24 weeks of gestation
2 Pregnancy-related complications: gestational diabetes mel-
litus (GDM); hypertension; breathing difficulties (feeling
of excessive breathlessness during pregnancy); anaemia;
and antepartum vaginal bleeding
3 Mode of delivery: normal vaginal delivery; assisted vaginal
delivery with forceps or vacuum; emergency and elective
caesarean section
4 Newborn outcomes: gestational age; birthweight; preterm
birth (<37 completed weeks of gestation); very preterm
birth (<32 completed weeks of gestation); birth centiles
– using customised centile calculations from NHS Gesta-
tion Network;11 admission to Special Care Baby Unit
(SCBU); neonatal resuscitation.
These measures were self-reported so cannot be precisely
defined. They are the individual impressions of the respon-
dents. The questionnaire was not piloted nor validated but
feedback on clarity and feasibility was provided by a small
group of five patients.
Data collection
All potential recruits received information regarding the
proposed study, together with an explanatory letter, con-
sent form and prepaid envelope. After consenting to the
study, a research nurse (CF) telephoned all participants to
arrange a face-to-face or telephone interview. Our struc-
tured questionnaire entailed asking women to recall out-
comes for each of their individual pregnancies and
deliveries. To quantify the outcomes of this study, ques-
tions, asked in plain English, required ‘Yes’, ‘No’ or numer-
ical responses from the participants. Pregnancy-related
complications, delivery outcomes and newborn outcomes
were what these women had experienced or what had been
communicated to them by their respective clinical team
(obstetricians/midwives). Technical medical terminology in
the questionnaire was made easy for participants to under-
stand. Answering the questionnaire took approximately
20 minutes. Any omissions or ambiguities were clarified by
follow-up telephone conversations with the research nurse.
Statistics
All identifying details were anonymised and statistical anal-
yses were conducted using SPSS (v23). For the purposes of
statistical comparisons, participants were grouped into
three groups, namely m.3243A>G, other mutations and
comparison groups. Presence of pregnancy-related compli-
cations, mode of delivery, birth resuscitation requirement
and admissions to SCBU were dichotomised (yes/no) for
analysis, except for gestation and birthweights, of which
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absolute numbers were recorded. Data were expressed as
frequencies or means  standard deviation (SD) if nor-
mally distributed. Binominal data of each outcome measure
from these three groups underwent chi-square 3 9 2 analy-
sis (including Fisher’s exact test for counts below five), and
parametric data had one-way analysis of variance (ANOVA)
to look for any differences. A P-value < 0.05 (adjusted for
multiple testing using the Benjamini and Hochberg
method, where appropriate) was considered statistically sig-
nificant. If statistical analysis revealed any significant differ-
ences, groups were then compared with each other in pairs
using chi-square test or post-hoc Tukey’s test. Generalised
linear models were used to test the relationship between
genetic mutation and a variety of outcome measures, with
the individual unique maternal anonymised identifier
included as a random effect in all models to account for
multiple births per woman. Akaike Information Criteria
were used to assess the relative model fit.
Patient involvement
The idea for this research was first conceived following anec-
dotal reports of pregnancy-related complications and pre-
term deliveries raised by women at our Highly Specialised
NHS Service for Rare Mitochondrial Disorder clinic in New-
castle in 2013. Our questionnaire had also undergone scru-
tiny by patient focus groups and had subsequently been
enhanced by outcome measures that mattered to patients.
Results from this study had been made available to patients
in our Reproductive Advice clinics for mitochondrial disease.
Ethics and funding
This study obtained institutional ethical approval from
Sunderland NRES Committee (Ref 11/NE/0028) and com-
plied with the Declaration of Helsinki. This work received
support from the Wellcome Centre for Mitochondrial
Research (DT, RM, AL), Biomedical Research Council UK
(GSG) and the Medical Research Council UK (VN, HD,
DT and RM).
Results
Basic demographics of women
Eighty-two women with genetically confirmed mitochon-
drial disease agreed to participate; of whom six withdrew
and nine did not fulfil the inclusion criteria (nulligravida).
Of these 67 women who completed the questionnaire, 28
had the m.3243A>G mutation, 5 had the m.8344A>G
mutation, 8 had the large-scale single deletions of
mitochondrial DNA (mtDNA), 11 had the other mtDNA
mutations (m.15669G>A, m.5650A>G, m.14709T>C,
m.9176T>C, m.1053A>G, m.7587T>C, m.4267A>G) and 15
had nuclear genetic mutations (PEO1, TWNK, POLG,
RRM2B, ETFDH multiple deletions of mtDNA). None of
the women who were approached to be contemporaneous
comparisons declined initially. Although 80 of these women
agreed to participate, nine subsequently withdrew. Two
women who had twin pregnancies were omitted from
matching with the patient group, which only had single-
ton pregnancies. Consequently, there were 69 women in
the comparison group, 28 recruits with m.3243A>G muta-
tions and 39 recruits with other mitochondrial genetic
mutations to be studied (Figure 1). Only one of the
women with m.3243A>G was diagnosed at the birth of
their first child (from family pedigree tracing) and none
of the women with m.3243A>G considered themselves to
have any mitochondrial disease manifestations at the time
of their pregnancies.
The age of respondents at the time of pregnancy was not
statistically different between the m.3243A>G patient group
(27.1 years, SD = 4.7, 95% CI 25.9–28.3), the other muta-
tions patient group (27.3 years, SD = 6.5, 95% CI 26.0–
28.7) and the comparison group (27.8 years, SD = 4.9,
95% CI 27.0–28.7) as determined by one-way ANOVA
(F = 16.5, P = 1.00) despite the initial withdrawals from
the study (Table 1). Women in the other mutations group
(55.7 years, SD = 10.4, 95% CI 52.4–59.1) were older at
the time of interview than their comparisons (47.8 years,
SD = 12.0, 95% CI 44.9–50.7) and m.3243A>G mutation
(47.0 years, SD = 11.3, 95% CI 42.6–51.4). At the time of
recruitment, all three groups had similar mean weight
(F = 2.37, P = 0.343) and body mass index (F = 0.542,
P = 0.1.00). Although there were more smokers in the
patient groups (n = 10) than in the comparison group
(n = 4), these differences did not reach statistical signifi-
cance (P = 0.345). After accounting for multiple births,
there was no difference between all three groups in the
proportion of women reporting irregular periods or a his-
tory of miscarriages (Table 1). No significant difference
was observed in exercise tolerance between patient and
comparison groups before pregnancy.
Fetal loss
There were 87 reported pregnancies in the m.3243A>G
group, 99 pregnancies in the other mutations group and
172 pregnancies in the comparison group. The number of
pregnancies per respondent in all three groups did not dif-
fer significantly (P = 0.495). Women with m.3243A>G
reported 20 miscarriages while the other mutations and
comparison groups reported 10 and 31 miscarriages,
respectively. There were no significant differences in the
history of miscarriages among all three groups (P = 0.309).
Five women (three patients and two unaffected women)
had terminations; one patient and one unaffected woman
declined to provide reasons, while the other three women
terminated for medical reasons; trisomy 18 (unaffected
woman), spina bifida (patient) and chorionic villus biopsy
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(for m.3243A>G patient who had been diagnosed from
family pedigree before pregnancy). All four of the recorded
stillbirths occurred in two mitochondrial disease patients
(other mutations group, n = 1; m.3243A>G, n = 3). There
were insufficient details about their pregnancies with these
stillbirths for analysis of pregnancy-related complications
and birth.
Pregnancy-related complications
After accounting for pregnancy losses and incomplete data,
the number of pregnancies available for review was 62 in
the m.3243A>G, 87 in the other mutations and 139 in the
contemporaneous comparison groups (Table 2). Compar-
ison between these groups after accounting for multiple
births showed significant differences in three outcome
measures during pregnancy, namely GDM (P = 0.008),
problems with breathing (P = 0.03) and hypertension
(P < 0.001). GDM was reported in 10 of the 62 (16.1%)
m.3243A>G pregnancies, compared with only 3.4% in the
other mutations and 2.9% in the comparison groups.
Women with m.3243A>G (11.3%) experienced more
breathing difficulties during pregnancy than the other two
groups. More than a third of women in the m.3243A>G
(35.5%) group had hypertension whereas only 6.9% and
2.2% had hypertension in the other mutations and com-
parison groups, respectively (Figure 2). Odds of having
GDM (OR 8.2, 95% CI 1.3–50.1), breathing difficulties
(OR 7.8, 95% CI 1.0–59.1) and hypertension (OR 8.2, 95%
CI 3.1–21.5) were higher in pregnancies of mothers with
m.3243A>G than those in the unaffected group. There were
82 women with genetically-confirmed 
mitochondrial disease invited from 
UK MRC MitoCohort
80 women without mitochondrial disease
69 comparisons
28 m.3243A>G 39 other mitochondrial 
genetic mutations
139 pregnancies & births 87 pregnancies & births62 pregnancies & births
9 withdrew
2 excluded a
6 withdrew
9 nulligravida
Excluded:
31 PL b
2 TOP c
Excluded:
20 PL b
2 TOP c
Excluded:
10 PL b
1 TOP c
67 patients
3 incomplete d 1 incomplete d
Face-to-face or telephone interview with structured questionnaire about previous pregnancies
Figure 1. Participation flow chart. aTwo women excluded because of twin pregnancies. bPL, pregnancy loss or miscarriage; cTOP, termination of
pregnancy. dIncomplete for analysis – no reliable pregnancy details disclosed on stillbirths.
Table 1. Summary of basic demographics of women in this study
m.3243A>G Other mutations Comparison P-value
Number of women eligible 28 39 69
Mean age at delivery (years) 27.1 (4.7, 26–28) 26.0 (6.5, 16–47) 27.8 (4.9, 27–29) 0.609
Mean weight (kg) 60.9 (15.1, 40–107) 66.1 (13.7, 44–114) 67.9 (14.3, 44–114) 0.343
Mean body mass index (kg/m2) 24.2 (6.0, 18–46) 25.2 (5.8, 18–44) 25.4 (4.7, 20–48) 0.609
Mean age at interview (years) 47.0 (11.3, 26–72) 55.7 (10.4, 32–72) 47.8 (12.0, 22–76) <0.001
Women with history of smoking 4 (14.3%) 6 (15.4%) 4 (5.8%) 0.345
Women reporting regular periods 25 (89.3%) 37 (94.9%) 57 (82.6%) 0.345
Women with history of miscarriage 11 (39.3%) 9 (23.1%) 18 (26.1%) 0.437
Number of miscarriages 20 10 31 0.309
Number of terminations of pregnancy 2 1 2 0.364
Number of incomplete data 3 1 0 0.309
One-way ANOVA used to compare differences of age at delivery, weight, body mass index and age at interview among the three groups. Results
expressed as mean followed by (SD, 95% CI). Categorical or nominal data expressed in absolute numbers followed by (%) and compared
between all three groups using chi-square or Fisher’s exact test. P-value < 0.05 was deemed statistically significant among three groups, after
adjustment for multiple testing
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no statistical differences in bleeding (P = 0.144) and anae-
mia (P = 0.531) during pregnancies between all three
groups. When complications were reviewed together, again
after accounting for multiple births per mother, women
with m3243A>G had significantly more complications as a
whole than women in the other two groups (P = 0.006).
There were significantly more complications for first preg-
nancies when compared with subsequent pregnancies
(P = 0.015).
Mode of delivery
Only 50% of the pregnancies of mothers with m.3243A>G
mutations were delivered vaginally without any interven-
tions, in contrast to 66.7% in the other mutations group
and 73.4% in the comparison group (P = 0.01) (Figure 3).
Emergency caesarean section was the second most likely
mode of delivery after normal vaginal delivery for carriers
of m.3243A>G mutations (24.2%). Both other mutations
(10.3%) and comparison (7.2%) groups had significantly
lower emergency caesarean section rates (P = 0.008).
Hence, pregnancies of women with m.3243A>G had much
higher odds compared with unaffected women (OR 7.6,
95% CI 2.3–36.1) to undergo emergency caesarean sections,
after accounting for multiple births per woman. Other
modes of delivery, including forceps, vacuum delivery, and
elective caesarean section, showed no statistical difference
between all three groups.
Newborn outcomes
More than half (53.3%) of the 62 live births to women
with m.3243A>G were preterm, or <37 weeks. Compared
with the comparison group (7.3%) and the other muta-
tions group (9.2%), these differences were statistically sig-
nificant (P < 0.001). There were also significantly more
very preterm babies delivered at <32 weeks (12.9%) to
mothers with m.3243A>G than the comparison group
(0.7%) and the other mutations (2.3%) group (P < 0.001).
Mothers with m.3243A>G had a much higher risk of hav-
ing very preterm babies (OR = 7.6, 95% CI 1.6–36.1) and
or preterm babies (OR = 41.2, 95% CI 3.3–507.3) than
unaffected women. At birth, about one in five babies of
m.3243A>G mothers required resuscitation. Number of
admissions to SCBU of these babies was significantly higher
than for babies born to the other two groups (P < 0.001)
Table 2. Summary of outcomes for all pregnancies analysed in the study
m.3243A>G Other mutations Comparison P-value
Number of pregnancies (%) 62 (100) 87 (100) 139 (100) 0.495
Problems during pregnancy
During your pregnancy, did you experience any of the following complications?
Bleeding (%) 16 (25.8) 11 (12.6) 24 (17.3) 0.144
Anaemia (%) 13 (21.0) 14 (16.1) 31 (22.3) 0.531
Diabetes of pregnancy (%) 10 (16.1) 3 (3.4) 4 (2.9) 0.005
Problems with breathing (%) 7 (11.3) 6 (6.9) 3 (2.2) 0.030
High blood pressure (%) 22 (35.5) 11 (12.6) 16 (11.5) <0.001
Mode of delivery
Did you have?
Normal vaginal delivery (%) 31 (50.0) 58 (66.7) 102 (73.4) 0.010
Forceps or vacuum delivery (%) 12 (19.4) 13 (14.9) 21 (15.1) 0.709
Elective caesarean section (%) 4 (6.5) 7 (8.0) 6 (4.3) 0.619
Emergency caesarean section (%) 15 (24.2) 9 (10.3) 10 (7.2) 0.008
Newborn outcome
Mean gestation (days) (95% CI) 253 (245–261) 277 (273–280) 279 (277–281) <0.001
Mean birth weight (g) (95% CI) 2779 (2529-3029) 3313 (3170-3456) 3429 (3314–3545) <0.001
Median birth centiles 58.5th 51st 58th 0.329
Number of babies < 37 weeks (%) 33 (53.2) 8 (9.2) 10 (7.3) <0.001
Number of babies < 32 weeks (%) 8 (12.9) 2 (2.3) 1 (0.7) <0.001
Did your baby require resuscitation (at birth)?
Yes (%) 13 (21.0) 7 (8.0) 8 (5.8) 0.004
Did your baby require admission to special care?
Yes (%) 33 (53.2) 11 (12.6) 22 (15.8) <0.001
Bold values denote P < 0.05.
Categorical or nominal data expressed in absolute numbers followed by (%) and compared between all three groups using chi-square or Fisher’s
exact test. One-way ANOVA used to compare differences of gestation days and birthweight among the three groups. Results expressed as mean
followed by (SD, 95% CI). P-value < 0.05 was deemed statistically significant among three groups, after adjustment for multiple testing
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(Figure 4). Babies born to mothers with the m.3243A>G
mutation had more than six times the risk of requiring
resuscitation at birth (OR = 6.7, 95% CI 1.9–23.7) and 11
times the risk of admission to SCBU (OR = 11.2, 95% CI
3.5–36.1) compared with babies born to unaffected mothers
in the comparison group.
Comparison of gestational age (F = 38.7, P < 0.001) and
birthweight (F = 16.2, P < 0.001) of babies born to moth-
ers in all three groups showed significant differences.
Post-hoc comparisons using the Tukey honestly significant
difference test demonstrated that the mean gestational age
(in days) and birthweight (in grams) for the m.3243A>G
group were both significantly different from those reported
in the comparison and other mutations group (P < 0.001)
Once multiple births were accounted for, m.3243A>G
births occurred on average 26 days earlier than in the com-
parison group. Gestational age at birth in the other muta-
tions group did not significantly differ from those in the
comparison group. Given that the babies born early were
likely to have lower birthweight, a customised birth centile
was plotted for each child. Comparisons of birth centiles
among all three groups did not show a significant differ-
ence (F = 1.12, P = 0.329) (Figure 4). Taken together,
these observations suggested that babies of mothers with
m.3243A>G were born significantly earlier, but not with
lower birthweights after correcting for gestation (i.e. there
was no increase in smallness for gestational age).
Discussion
Main findings
Our study highlighted that pregnancies of women who had
m.3243A>G, the most common genetic mutation for adult
mitochondrial disease, had significantly increased risks of
occurrence of GDM, breathing difficulties and hypertension
than a contemporaneous comparison group. Despite being
asymptomatic at the time of their pregnancy only half of
the women with the m.3243A>G mutation had a normal
vaginal delivery and almost half of the remaining pregnan-
cies were delivered by emergency caesarean section. Babies
born to mothers with m.3243A>G mutations were born at
significantly earlier gestations with correspondingly lower
birthweights than both the other mutations and the unaf-
fected comparison groups. More than half of these babies
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Figure 2. Percentage of pregnancies in which women had experienced bleeding, anaemia, gestational diabetes, breathing problems and high blood
pressure. Women with m.3243A>G experienced significantly more (gestational) diabetes and high blood pressure during pregnancies than women in
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were preterm, probably accounting for the high SCBU
admission rates.
Strengths
The effects of pregnancy on women with mitochondrial
disease have not been well-studied, partly due to its rarity.
The UK Mitochondrial Disease Patient Cohort, from which
this study was derived, is one of the largest cohorts of liv-
ing patients with genetically confirmed mitochondrial dis-
ease in the world.7 We learned from women recruited from
this cohort that there are a number of under-recognised
complications of pregnancy and delivery in women with
mitochondrial disease, in particular the m.3243A>G muta-
tion, which require clinical vigilance and pathophysiological
explanation. One further advantage of this study was hav-
ing two distinct groups for comparison; the first
comprising mothers with pathogenic mitochondrial muta-
tions other than m.3243A>G and the second, a group of
women not known to harbour a mitochondrial disease-
causing mutation.
Limitations
A small number of patients and unaffected women with-
drew consent for the study after our age-matching pro-
cess. Although these dropouts affected the age differences
in the other mutations group, they did not significantly
affect the basic demographics of this study, especially the age
at which these women had their pregnancies. The other
mutations group had older participants, reflecting the later
age of onset of disease for some mitochondrial genetic
defects. Although this study design was primarily reliant on
maternal recall of pregnancy and childbirth, with resultant
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Figure 4. Newborn outcomes. (A) Gestation of babies (in days); (B) Birthweight of babies (in grams). Babies born to mothers with m.3243A>G had
significantly lower gestational age and birthweight than both other mutations and comparison groups. (C) Birthweight centile corrected for gestation.
No difference between all three groups. (D) Babies born to mothers with m.3243A>G had significantly more resuscitations at birth and admissions to
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possibility of recall bias due to increasing age and time since
relevant pregnancy, it has been demonstrated by a number
of studies that such recollections can be clear and accu-
rate.12,13 Other drawbacks of a retrospective questionnaire
included the presence of self-selection bias among volunteers
who might either over-report or under-report their unpleas-
ant experiences. Our patient-based questionnaire study also
lacked the release of hospital and/or midwifery records to
confirm the reported experiences of these women. Partici-
pants might interpret certain medical terminology dissimilarly
from healthcare professionals even though we clarified these
via telephone or face-to-face interviews. Finally, there could
also be confounding factors, such as the changing trends of
pregnancies and deliveries over time. Most of the pregnancies
and deliveries in this study occurred in the 1990s.
Interpretation
Among the pregnancy-related complications in this study,
reports of diabetes during pregnancies were significantly
higher for mothers with m.3243A>G than in the other two
study groups. The population-prevalence of GDM was
widely estimated at between 1 and 3%14 before the revised
WHO criteria in 2010, which is consistent with the preva-
lence in women in the unaffected comparison group (2.9%).
This emphasises the relatively high rates of GDM in
m.3243A>G (16.1%). Diabetes mellitus, which is a recog-
nised phenotype in 38% of m.3243A>G patients,15 could
account for their poor glycaemic control during pregnancy.
Our findings contrast with a study of pregnant women with
m.3243A>G mutation in the Netherlands that reported a
prevalence of GDM of only 11%,10 although this is still
higher than in the general pregnant population. Differences
in the definition of obstetric complications and different
practices as well as varying levels of heteroplasmy might limit
any direct comparisons.
Another pregnancy-related complication observed to be
increased was hypertension during pregnancy. More than
a third of the pregnancies in women with m.3243A>G
had reported high blood pressure compared with those in
the comparison group (11.5%) and to international com-
parative studies of 3.6–9.1%.16 High rates of this compli-
cation could be attributed to the discrepancy in the
interpretation of high blood pressure experienced by or
conveyed to patients and the precise technical definition
of pregnancy-related hypertension among clinicians. Given
the reliance on precise clinical parameters for a diagnosis
of pre-eclampsia and the limited public understanding of
the term we elected not to pursue questions related to this
specific diagnosis in the questionnaire. Contrary to dia-
betes, hypertension is not a known manifestation of
m.3243A>G mutations. Placental function is likely to be a
key determinant, particularly in relation to the develop-
ment of hypertension and preterm deliveries. Proteomic
alterations relevant to the mitochondrial respiratory chain
function and fatty acid oxidation have been reported pre-
viously in placentas from women with pre-eclampsia,
where morphological abnormalities of mitochondria were
also noted.2,17 Recently, impaired mitochondrial function
has been demonstrated to play an important role in the
development of hypertension and reduced fetal weight in
a rat model of pre-eclampsia.18
At the time of delivery, half of the 62 births to mothers
with the m.3243A>G mutation required obstetric interven-
tions (instrumental or caesarean section). The rate of
interventional delivery in this cohort suggests that the
m.3243A>G mutation might be influential in determining
the response to metabolic stress associated with the onset
of labour. Without the medical records, it was not possi-
ble to determine the exact indications for obstetric inter-
ventions. As this study collected information on deliveries
in the 1990s from the participant, the rates of elective and
emergency caesarean sections among m.3243A>G deliveries
were unusually high (30.7%) in an era when the rates of
these interventions in the UK ranged from 12% in 1990
to 20% in 2000.19–21 From our limited retrospective
assessment, it was difficult to know if the complications
observed in pregnancy and emergency caesarean sections
were mostly determined by fetal or maternal factors but
this could be pursued in prospective studies. Another
observation in this study was that there were more pre-
term babies (<37 weeks) born to mothers with this
m.3243A>G mutation even after accounting for multiple
births. As a result, they were also more likely to require
admission to SCBU. This high rate of prematurity appears
to be specific to women with the m.3243A>G mutation
and was not observed in women with other pathogenic
mitochondrial mutations. Our rate of preterm delivery
(53.2%) in these women was much higher than that in
the Netherlands study (11%).10
Although the pathophysiological process may remain
undetermined at present, it is clear from our current study
that women harbouring m.3243A>G are at much greater
risk of complicated pregnancies and deliveries than those
with other forms of mitochondrial disease, who seem to
incur very little, if any, additional risk. Our findings have
important implications for the obstetric management of
pregnancy and delivery in women with the m.3243A>G
mutations, even though they might not have any mito-
chondrial disease manifestation at the time of pregnancy.
Women of reproductive age who are discovered to be carri-
ers of the m.3243A>G mutation should be made aware of
the increased risks in pregnancy and delivery. We feel this
is pertinent given the increasing range of reproductive
options (prenatal genetic testing, pre-implantation genetic
diagnosis and mitochondrial donation) that are already
available to women who harbour pathogenic mutations
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associated with mitochondrial disease.22,23 Although the
novel mitochondrial donation technique might be consid-
ered an appropriate reproductive treatment option for
some women harbouring the m.3243A>G mutation, it
remains unclear if women with the m.3243A>G mutations
but pregnant with a fetus with minimal (<2%) mutation
load will experience similar pregnancy-related complica-
tions to those reported in this study. Close clinical scrutiny
of these mitochondrial donation pregnancies may help to
answer the question of whether these complications are a
result of fetal or maternal factors.
Conclusions
Based on our study, we suggest that women with mitochon-
drial disease, especially those due to the m.3243A>G muta-
tions, are more likely to experience pregnancy-related
problems such as hypertension, GDM, breathing difficulties,
emergency caesarean section and preterm birth. Not only will
these findings be useful to clinicians in the counselling of
expectant women with mitochondrial disease, but they form
the basis for future pathophysiological studies into the under-
lying mechanism of mitochondrial disease in pregnancy.
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